The information provided by the serological tests is a potential still little exploited

In recent weeks, the third dose of vaccine against Covid 19, green pass with a temporal expiry after the vaccination cycle and close tampons for the subjects who have decided not to vaccinate. We are still waiting for studies and evidence that indicate the duration of the protection based on cell immunity and antibodies, so the invitation is that of vaccinating.

The immune condition of the subject

However, it is always correct not to evaluate the subject’s immune condition for vaccination purposes? Those who have naturally contracted the virus and demonstrate that they have developed antibodies, today it is still obliged, to have the green pass, to undergo 2 doses of vaccine. It is really necessary? It may be useful to measure the amount of antibodies to know the level of one’s immune defenses?

The official indications recommend that they get vaccinated without carrying out checks, even if the situation is much more delicate. The vaccines are all effective, but not 100%. As you can be sure that you have responded to the vaccination doses without checks?

This question assumes even more relevance for fragile and immunosuppressed subjects that would require an even more careful and stringent verification of their condition. To date, serological tests are the only tool to monitor the actual immune response of a subject in a simple, quick and large -scale way.

The information provided by these tests

The information provided by these tests is a little exploited potential. If conducted in qualified health facilities, serological tests could also be used to support decisions in the vaccination area. Hypotheses are also emerging to consider the result of the serological tests as a security indicator: they can become an element of the green pass?

The presence of antibodies could be considered for safety in the workplace?

Today only the green pass applies as a guarantee, but does not contemplate the antibody positivity between the healing criteria: those who are healed from the disease, despite having developed antibodies, therefore seem discriminated against. The hope is that institutions attribute greater value to the use of serological tests, ensuring greater access to this important evaluation tool.

“The green pass in my view is a fair way to strongly encourage the vaccination that is giving excellent results in the containment of the pandemic, but above all in the reduction of serious forms of illness and mortality. On the other hand, the large -scale dosage of antibodies would be desirable with the right methods (only quantitative and not quick tests), to acquire more information on the individual duration of antibodies and on the level necessary in order to ensure protection as well as to improve knowledge on Virus/guest interactions. Therefore, the large -scale dosage of antibodies with the right methods if considered, with intellectual honesty, a work in progress.

I was the institutions, I would do it.”These are the words of the prof. Sergio Bernardini, Noto professor of clinical biochemistry and molecular biochemistry of the Tor Vergata University of Rome.